CIRCIO HOLDING ASA: INFORMATION ABOUT WARRANTS AND COMMENCEMENT OF TRADING

16 Feb 2026 07:00 CET

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,
IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA,
CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT
CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 16 February 2026: Reference is made to the stock exchange announcement
published by Circio Holding ASA (the "Company") on 12 February 2026 regarding
the registration of share capital increases in connection with the rights
issue raising gross proceeds of NOK 50 million (the "Rights Issue") and in
connection with the private placement of 15,018,945 new shares (the "Private
Placement").

A total of 67,680,945 warrants (the "Warrants") have been issued on ISIN NO
0013711523 in connection with the Rights Issue (including the warrants issued
as commission to the pre-subscribers in the Rights Issue) and the Private
Placement.
The Warrants will be listed and tradable on the Oslo Stock Exchange under the
ticker code "CRNAS". The trading period for the Warrants commences today, 16
February 2026, and will end four trading days prior to 9 June 2026 at 16.30
hours (CEST).

Each Warrant will give the holder the right to subscribe for and be allocated
one (1) new share in the Company at an exercise price equal to 80% of the
volume-weighted average price of the Company's shares on the Oslo Stock
Exchange in the period between 8 May 2026 to 22 May 2026, but not less than
the nominal value of Company's shares at the time of the Exercise Period (as
defined below).

The Warrants may be exercised in the period from 08:00 hours (CEST) on 26 May
2026 to 16:30 hours (CEST) on 9 June 2026 (the "Exercise Period"). Additional
information regarding the exercise of the Warrants will be provided closer to
the Exercise Period.

Any Warrants not exercised within 16:30 hours (CEST) on 9 June 2026 will have
no value and will lapse without compensation to the holder.

Selling and Transfer Restrictions:
The grant or purchase of Warrants by persons resident in, or who are citizens
of countries other than Norway or Sweden, may be affected by the laws of the
relevant jurisdiction. For a further description of such restrictions,
reference is made to the Section 11 "Selling and Transfer Restrictions" in the
securities note dated 13 January 2026 (the "Securities Note", and together
with a registration document dated 1 October 2025, and a registration document
supplement and summary dated 13 January 2026, comprise the "Prospectus").

Holders of Warrants who do not exercise Warrants to subscribe for new shares
in the Company may experience a dilution of their shareholding in the Company.
For a further description of such dilutive effect, reference is made to
Section 5.20 "Dilution" in the Securities Note.

For more information pertaining to the Warrants, please refer to the
Prospectus. The Prospectus is available on the Company's website:
https://www.circio.com/en/rightsissue2026/.

This information is subject to the disclosure requirements pursuant to the
Continuing Obligations and Section 5-12 of the Norwegian Securities Trading
Act.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 40-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology
program, TG01, through cost-efficient external academic and industry
collaborations. TG01 targets RAS-mutated cancers and is being tested in two
clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine
adjuvanted by STIMULON QS-21 licensed from Agenus Inc.

More information:
Access the news on Oslo Bors NewsWeb site